Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K. Abou‐Alfa, Bruno Sangro, George Lau et al.|NEJM Evidence|2022Cited by 1.4k
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyMilind Javle, Ghassan K. Abou‐Alfa, Sameek Roychowdhury et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 423
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinomaBruno Sangro, Anthony B. El-Khoueiry, Ignacio Melero et al.|Journal of Hepatology|2020Cited by 421
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.Ghassan K. Abou‐Alfa, Bruno Sangro, Stephen L. Chan et al.|Journal of Clinical Oncology|2022Cited by 398
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b studyJames J. Harding, Sebastián Mondaca, Michel Ducreux et al.|The Lancet Oncology|2023Cited by 243